Cipla partners with US-based Lilly for Yurpeak launch

Cipla has teamed up with Eli Lilly to distribute and promote Yurpeak (tirzepatide) in India. This marks as the second launch of the breakthrough diabetes and obesity drug after Mounjaro. The move aims to make the blockbuster treatment more accessible across India.

The deets: under the deal, Lilly will continue to manufacture and supply the drug, while Cipla handles distribution and promotion. 

Pricing for Yurpeak will remain the same as Mounjaro, and it’ll come in a KwikPen format with six dosing options, designed for personalised weekly use.

Why it matters: the partnership marks important step towards Cipla’s entry into the fast-growing obesity care segment while helping Lilly expand reach beyond major cities. With obesity and diabetes cases surging, wider access to tirzepatide, a dual-action GIP and GLP-1 agonist, could be a game-changer for chronic care in India.